Rezolute Inc. (RZLT) is a clinical-stage biopharmaceutical company that develops therapies for rare and metabolic diseases. The company's lead drug candidate, RZ358, is a potential treatment for congenital hyperinsulinism (CHI), a rare genetic disease that affects infants and can lead to severe hypoglycemia (low blood sugar) and brain damage. RZ358 has received orphan drug designation from the FDA, which provides incentives for the development of drugs for rare diseases. Rezolute is also developing RZ402, a potential treatment for diabetic macular edema, a complication of diabetes that affects the retina of the eye.
Rezolute Inc. (RZLT) is a clinical-stage biopharmaceutical company that develops therapies for rare and metabolic diseases. The company's lead drug candidate, RZ358, is a potential treatment for congenital hyperinsulinism (CHI), a rare genetic disease that affects infants and can lead to severe hypoglycemia (low blood sugar) and brain damage. RZ358 has received orphan drug designation from the FDA, which provides incentives for the development of drugs for rare diseases. Rezolute is also developing RZ402, a potential treatment for diabetic macular edema, a complication of diabetes that affects the retina of the eye.